Oral Phytochemical Composition for Dry AMD Inflammation Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There are no effective preventive measures or treatments available for patients suffering from dry age-related macular degeneration (AMD), a condition characterized by the thinning of the macula leading to blurred or reduced vision, with drusen accumulation and a pro-inflammatory environment contributing to the disease progression.

Innovation Solution

Oral administration of a synergistic combination of resveratrol, quercetin, and curcumin compounds in specific dosages to target the Toll-like receptor 4 (TLR4) pathway, reducing inflammation and drusen volume, and slowing geographic atrophy growth.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If vitamin and supplement formulations (AREDS and AREDS2) are used, then progression rates are reduced, but results are mixed and not sufficiently effective

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidconsistency of results

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the chemical parameters of the supplement formulation by selecting specific compounds (resveratrol, quercetin, curcumin) with defined molecular structures and dosages, moving from general vitamin formulations to targeted phytochemical combinations with proven anti-inflammatory and antioxidant properties

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention uses a composite formulation combining three specific phytochemical compounds (resveratrol, quercetin, and curcumin) that work synergistically to address multiple pathological mechanisms of AMD simultaneously, rather than relying on single vitamins or supplements

Inventive Principle:

Principle #40Composite materials

2Reliability

If anti-VEGF antibody injections are administered, then wet AMD is treated, but the treatment is invasive and does not address dry AMD

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidinvasiveness of treatment

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent replaces the mechanical/invasive injection method with oral administration of pharmacological compounds, substituting a minimally invasive systemic approach for direct intraocular injection while achieving comparable or superior therapeutic effects through the bloodstream

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The phytochemical formulation addresses multiple AMD types (both dry and wet forms) and multiple pathological mechanisms (inflammation, oxidative stress, drusen accumulation) simultaneously, making it a universal treatment approach rather than being limited to a single AMD subtype

Inventive Principle:

Principle #6Universality (Multi-functionality)

3Object-affected harmful factors

If TLR4 pathway is targeted, then inflammation is reduced and drusen volume decreases, but requires specific compound combinations

Engineering Contradiction:

Improveinflammation levelVSAvoidcomplexity of compound combination

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent uses phytochemical compounds (resveratrol, quercetin, curcumin) as intermediary substances that naturally bind to and modulate the TLR4 receptor pathway, acting as mediators between the administered supplement and the inflammatory response without requiring direct genetic or cellular manipulation

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12551453B2Compositions and methods of treating age-related macular degeneration

Publication Date: 2026.02.17 KNEPPER PAUL A

AI summary

Age-related macular degeneration (AMD) is treated by administration of a stilbene, a flavonol, and curcumin or a biologically active curcumin analog to a patient afflicted with AMD.